The Role of Glasses in Aseptic Production: A Detail Often Ignored - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Role of Glasses in Aseptic Production: A Detail Often Ignored


Pharmaceutical Technology





Hood, suit, faceplate, cover shoes, gloves: these are the necessary items of clothing when operating in A- and B-grade areas. The principal purpose of protective clothing is to minimize the risk of microbiological contamination caused by personnel. Thus, protective garments should not release fibers and must be able to contain particles produced and released by the body.

But how can we ensure that protective garments are not themselves vehicles of contamination? And how can we ensure that cleaning and sterilization processes are effective and do not alter the characteristics of the garments? We attempted to answer these questions, concentrating our attention mainly on glasses (in general, on individual protection devices usually referred to as masks).

Because glasses are not disposable, we must consider that stress conditions such as repeated sterilizations may compromise their use. The glasses may lose functionality and the components might be damaged, resulting in the release of contaminating material.


Figure 1: The type of glasses evaluated
We prepared a study protocol to help verify the following aspects:
  • the glasses' ability to endure repeated sterilization processes without suffering alterations;
  • the ability of the sterilization process to obtain a 12-log reduction of the starting microbiological charge.

We chose to verify only the steam-sterilization cycle because it is the process most commonly used in the pharmaceutical industry, although glasses also are sterilized using other methods (γ-rays, ethylene oxide, etc.).


Table I: Characteristics of the glasses used.
For our tests, we used glasses (see Figure 1) with the characteristics outlined in Table I. Tests were conducted to verify that it was possible to subject glasses to repeated sterilization cycles without any alterations that could compromise their usefulness. Glasses in the trial were subjected to repeated steam sterilization cycles (temperature = 121 ± 1 °C, time = 30 min) according to the outline in Table II. At the end of the fixed sterilization cycles, the glasses were evaluated for adherence to the facial conformation, lens transmission, and particle release.

The effectiveness of the sterilization process is a probabilistic function depending on the number of microorganisms present, the thermic resistance of these microorganisms, and the quantity of heat supplied. Therefore, determining the quantity of heat that is necessary to attain the 12-log reduction in the microorganism population to ensure sterility depends entirely on the thermic resistance of the present microorganisms.


Table II: Glasses subjected to steam sterilization cycles.
The thermic resistance of the microorganisms was evaluated by verifying the D value as the time necessary to reduce 90% of the population of present microorganisms (1 log) in specific sterilization conditions. Even if the sterilization cycle recommended by the producer is a typical overkill cycle, it is necessary to evaluate the D value of the microorganism in a trial because this value strongly depends on the possible interactions between the microorganisms and the material on which they are found.


ADVERTISEMENT

RELATED CONTENT
The Role of Glasses in Aseptic Production: A Detail Often Ignored
Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
The Effect of Carrier Material on the Measured Resistance of Spores
The Importance of Pre-Use Integrity Testing in Sterilizing Filtration
Radiation Sterilization of Parenterals
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here